{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"34"}]}],"title":"Good/very good"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"18"}]}],"title":"Intermediate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"8"}]}],"title":"Poor"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"19"}]}],"title":"Very poor"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"13"}]}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"92"},{"groupId":"OG002","value":"92"}],"units":"Participants"}],"description":"Cytogenetic risk group is used to identify cytogenetic abnormalities.","groups":[{"description":"Patients receive azacitidine SC or IV on days 1-7 or days 1-5 and 8-9, and lenalidomide PO QD on days 1-21. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nLenalidomide: Given PO","id":"OG000","title":"Arm 1: Azacitidine/Lenalidomide"},{"description":"Patients receive azacitidine as in Arm 1. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV","id":"OG001","title":"Arm 2: Azacitidine"},{"description":"Patients receive azacitidine as in Arm 1 and vorinostat PO BID on days 3-9. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nVorinostat: Given PO","id":"OG002","title":"Arm 3: Azacitidine/Vorinostat"}],"paramType":"NUMBER","populationDescription":"Analysis includes eligible patients only.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Pre-study Cytogenetic Abnormalities","type":"SECONDARY","unitOfMeasure":"participants"}